Filing search / Centessa Pharmaceuticals plc / "Safety"

424B5

CNTA Centessa Pharmaceuticals plc

13 Sep 24

Prospectus supplement for primary offering

4:02pm

latency of 32 minutes as measured by the MWT. ORX750 was also shown to have a favorable safety and tolerability profile with no observations of frequently … . The Phase 1 clinical study is an ongoing first-in-human, randomized, placebo-controlled study designed to evaluate the safety, tolerability

8-K

EX-1.1

CNTA Centessa Pharmaceuticals plc

13 Sep 24

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

4:00pm

and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants … , quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or Regulatory Authorities; (vi) those foreign

424B5

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Prospectus supplement for primary offering

4:40pm

to restore normative wakefulness2 with a mean sleep latency of 32 minutes as measured by the MWT. ORX750 was also shown to have a favorable safety … to evaluate the safety, tolerability and pharmacokinetics (PK) of single-ascending doses (“SAD”) and multiple-ascending doses (“MAD”) of ORX750

S-3ASR

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Automatic shelf registration

4:01pm

programs, including ORX750, SerpinPC and LB101, will be predictive of results of further clinical trials; the safety and tolerability profile of our

S-3ASR

EX-4.6

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Automatic shelf registration

4:01pm

or steel engraved borders or mechanically reproduced on safety paper or may be produced in any other manner, all as determined by the officers executing

S-3ASR

EX-4.4

9ibvkzud3jdmr47

11 Sep 24

Automatic shelf registration

4:01pm

8-K

EX-99.2

jmn2dkdjj

10 Sep 24

Regulation FD Disclosure

7:08am

8-K

EX-99.1

ddg3a 4kpvwi30nduin

10 Sep 24

Regulation FD Disclosure

7:08am

8-K

4qw12

10 Sep 24

Regulation FD Disclosure

7:08am

8-K

EX-99.1

8fzfkdx5gj

13 Aug 24

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for Anticipated Upcoming Program Milestones

7:15am

8-K

EX-99.1

1rq5d0h 4g

10 Jun 24

Departure of Directors or Certain Officers

7:13am

DEFA14A

es317jz49r68vdycu5fc

20 May 24

Additional proxy soliciting materials

8:48pm

8-K

EX-99.1

ckr43

13 May 24

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for Anticipated Upcoming Program Milestones

4:23pm

PRE 14A

cep5ysvww 8a43

26 Apr 24

Preliminary proxy

4:36pm

424B5

y7l5uvf

24 Apr 24

Prospectus supplement for primary offering

8:53pm

8-K

EX-1.1

teil rrrajc46

24 Apr 24

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

9:26am

424B5

xk91m0y7k1 usk5uomm6

23 Apr 24

Prospectus supplement for primary offering

5:16pm